Zacks Research Has Negative Outlook for ALLO Q2 Earnings

Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Equities researchers at Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for shares of Allogene Therapeutics in a research report issued to clients and investors on Thursday, January 9th. Zacks Research analyst R. Department now forecasts that the company will post earnings of ($0.38) per share for the quarter, down from their previous forecast of ($0.37). The consensus estimate for Allogene Therapeutics’ current full-year earnings is ($1.27) per share. Zacks Research also issued estimates for Allogene Therapeutics’ Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.57) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.47) EPS and FY2026 earnings at ($1.75) EPS.

Several other brokerages have also recently commented on ALLO. Piper Sandler dropped their target price on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Allogene Therapeutics in a report on Friday, November 8th. Finally, William Blair reissued an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.73.

Allogene Therapeutics Stock Performance

Shares of NASDAQ ALLO opened at $1.92 on Monday. Allogene Therapeutics has a 52 week low of $1.78 and a 52 week high of $5.78. The stock’s fifty day moving average is $2.30 and its 200 day moving average is $2.53. The stock has a market capitalization of $402.57 million, a P/E ratio of -1.23 and a beta of 0.86.

Hedge Funds Weigh In On Allogene Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Nordea Investment Management AB boosted its stake in shares of Allogene Therapeutics by 2.1% during the fourth quarter. Nordea Investment Management AB now owns 460,641 shares of the company’s stock valued at $986,000 after purchasing an additional 9,635 shares in the last quarter. Barclays PLC increased its position in Allogene Therapeutics by 101.5% in the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock valued at $959,000 after acquiring an additional 172,745 shares during the period. Geode Capital Management LLC increased its position in Allogene Therapeutics by 14.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after acquiring an additional 407,070 shares during the period. MML Investors Services LLC bought a new position in shares of Allogene Therapeutics during the third quarter valued at $56,000. Finally, Zacks Investment Management acquired a new position in shares of Allogene Therapeutics during the third quarter worth $1,446,000. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).